Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

enVVeno Medical Corporation Common Stock

NVNO

enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $5.63 – $6.10
Volume 10,462
Market cap $4M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$4.13M
Price / earnings
—
Price / book
0.24×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.09×

Profitability

Earnings per share
-$22.38
Return on assets
-79.8%
Return on equity
-92.02%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
7.35×
Quick ratio
7.35×
Cash ratio
1×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$13.41M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for NVNO, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$1.66M$1.72M$1.95M$2.07M$2.3M$4.16M$2.4M$3.19M
Research and development$2.88M$2.08M$2.11M$1.95M$2.59M$2.89M$2.56M$3.51M
Total operating expenses$4.53M$3.8M$4.06M$4.01M$4.88M$7.05M$4.95M$6.7M
Operating income-$4.53M-$3.8M-$4.06M-$4.01M-$4.88M-$7.05M-$4.95M-$6.7M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$4.37M-$3.6M-$3.85M-$3.74M-$4.54M-$6.69M-$4.5M-$6.23M
Income taxes$0$0$0$0$0$0$0$0
Net income-$4.37M-$3.6M-$3.85M-$3.74M-$4.54M-$6.69M-$4.5M-$6.23M
Net income attributable to common shareholders-$4.37M-$3.6M-$3.85M-$3.74M-$4.54M-$6.69M-$4.5M-$6.23M
EBITDA-$4.52M-$3.86M-$4.03M-$3.98M-$4.85M-$7.02M-$4.91M-$6.66M
Basic earnings per share-$6.29-$5.37-$5.89-$6.04-$7.89-$11.52-$7.75-$10.68
Diluted earnings per share-$6.29-$5.37-$5.89-$6.04-$7.89-$11.52-$7.75-$10.68

Recent news

Company coverage with links to the original publishers.

Publication times in UTC

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jan 20, 20261-for-35reverse split
Nov 30, 20201-for-25reverse split